Blog

• Excellent momentum for theranostics sales: +43%
• Second-quarter revenue growth: +12%

Croissy-Beaubourg and Montpellier, July 25, 2017, 6 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in vitro diagnostics and theranostics, today reported its consolidated revenues to June 30, 2017.

In the second quarter of 2017, Theradiag recorded a +12% increase in revenues compared with the same quarter of 2016, following the 5% growth recorded in the first quarter of 2017, enabling its consolidated revenues to total €5 million at the end of June 2017.

Over the first six months of the year, the Theranostics Business Unit recorded a +43% jump in sales to €2.4 million; the main reason for this growth was the volume of export sales, despite the launch of activity in the United States being slower than expected.

Sales of other IVD products were down 10%, in line with the trend recorded over the first quarter according to our expectations. However, the effective launch of BioCLIA has been postponed, due to a delay, in adapting to standards as well as our clients’ expectations in Europe, and due to discussions regarding contract renegotiations initiated by our partner HOB biotech.

International sales totaled €2.7 million, and this activity now accounts for 53% of total revenues.

Michel Finance, Theradiag’s Chief Executive Officer, commented: “The growth in our theranostics sales and the agreements signed with pharmaceutical companies confirm our strategic development choice. The €4 million capital increase carried out in the second quarter strengthens our development capabilities”.

Theradiag’s Annual General Meeting confirmed the appointment to the Board of Directors of Dominique Costantini, Dominique Takizawa and Vincent Fert, previously co-opted by the Board., and the appointment to the Board of John Li, President and CEO of HOB Biotech Group.

Having obtained his Masters degree in economics from Ohio State University in the United States, John Li has worked in management positions at Alcon, Black&Decker and Brady Corp. In 2007, he founded HOB Biotech, which has since become the market leader in allergy diagnostics and a major player in the diagnosticis of auto-immune diseases in China.